Modafinil for the Treatment of Fatigue in Lung Cancer V9.0
NCT ID: NCT00829322
Last Updated: 2013-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
208 participants
INTERVENTIONAL
2009-02-28
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Central nervous system (CNS) stimulants are the only class of drug established as being directly effective in relieving fatigue. Traditional stimulants, such as methylphenidate (Ritalin), can cause side-effects such as difficulty sleeping at night and anxiety. Modafinil is a relatively new stimulant with few side-effects. There is increasing evidence that modafinil can reduce fatigue in healthy individuals and patients with chronic, non-cancer conditions. No good quality studies have been published evaluating modafinil in patients with cancer, despite multiple calls for such research to be undertaken.
The investigators have completed a small study to determine the feasibility of undertaking a larger, high quality study to assess the effect of modafinil on fatigue in patients with lung cancer. Modafinil appeared to improve fatigue rapidly and was not associated with serious side-effects. Ten of the fifteen patients who completed the study chose to continue modafinil long-term. However, the study was too small for definite conclusions to be drawn.
This larger, definitive study, funded by a National Cancer Research Institute research award, will establish more clearly whether modafinil can improve fatigue in patients with lung cancer. Two hundred and six patients will be recruited from a number of sites across the UK. Half of the patients will take modafinil, and the other half will take a 'dummy' tablet every day for a month. The fatigue levels of the two groups will be compared. Confirmation that modafinil can relieve cancer-related fatigue could have a highly significant impact on the quality of life of the very large number of patients suffering from this common and distressing symptom.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
Modafinil
Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
Control group
Placebo
One capsule daily for 14 days, increasing to two capsules daily for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil
Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
Placebo
One capsule daily for 14 days, increasing to two capsules daily for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, aged 18 years or above
* Diagnosed with NSCLC
* Stage 3a, 3b or stage 4 disease, or recurrent disease after surgery or radiotherapy
* WHO performance status of 0-2
* Participant has a screening score of 5 or more in a 10-point numerical rating scale (NRS) of fatigue severity within two weeks of enrolment
* Able (in the investigator's opinion) and willing to comply with all study requirements, including ability to participate for in study for 28 days
* Willing to allow his or her General Practitioner to be notified of participation in the study.
Exclusion Criteria
* Commenced on an EGFR tyrosine kinase inhibitors eg Gefitinib and Erlotinib within the last 6 weeks.
* Commenced on antidepressants or steroids (corticosteroids and progestational steroids) within the last 2 weeks
* Received blood transfusion within the last 2 weeks
* Potentially fertile woman of child-bearing age
* Major anxiety requiring intervention in secondary care
* History of arrhythmia requiring medical intervention
* Uncontrolled hypertension with blood pressure greater than 160/100 mmHg
* History of cor pulmonale or left ventricular hypertrophy
* Currently taking warfarin
* Previous adverse reaction to modafinil or other CNS stimulant
* Scheduled elective surgery or other procedures requiring general anaesthesia during the study
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or affect the participant's ability to participate in the study
* Currently participating in another research study involving an investigational product.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bee Wee, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stoke Mandeville Hospital
Aylesbury, , United Kingdom
Macclesfield District Hospital
Cheshire, , United Kingdom
University Hospital of North Tees
County Durham, , United Kingdom
Basildon and Thurrock University Hospitals
Essex, , United Kingdom
Basingstoke and North Hampshire Hospital
Hampshire, , United Kingdom
East Kent University Hospitals
Kent, , United Kingdom
Queen Elizabeth Hospital
Kings Lynn, , United Kingdom
University Hospital
Llandough, , United Kingdom
Royal Marsden Hospital Fulham Road
London, , United Kingdom
Royal Marsden Hospital Sutton
London, , United Kingdom
St George's Hospital
London, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
Wythenshawe Hospital
Manchester, , United Kingdom
James Cook University Hospital
Middlesbrough, , United Kingdom
Harrogate and District NHS Foundation Trust
North Yorks, , United Kingdom
Churchill Hospital
Oxford, , United Kingdom
Papworth Hospital
Papworth Everard, , United Kingdom
Withybush General Hospital
Pembrokeshire, , United Kingdom
Peterborough District Hospital
Peterborough, , United Kingdom
Royal Surrey County Hospital
Surrey, , United Kingdom
Great Western Hospital
Swindon, , United Kingdom
Hillingdon Hospital
Uxbridge, , United Kingdom
Calderdale and Huddersfield NHS Foundation Trust
West Yorkshire, , United Kingdom
Mid Yorkshire Hospital NHS Trust
West Yorkshire, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, O'Brien M, Stone P, Benepal T, Bates N, Wee B. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014 Jun 20;32(18):1882-8. doi: 10.1200/JCO.2013.54.4346. Epub 2014 Apr 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Modafinil/lung/09
Identifier Type: -
Identifier Source: org_study_id